Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tezosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.80 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tezosentan SCHEMBL29409604 | 1.00 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL387772 | 0.99 | EDNRA (0.79) | EDNRAEDNRB | |
| Tezosentan SCHEMBL1230886 | 0.99 | EDNRA (0.79) | EDNRAEDNRB | |
| Tezosentan SCHEMBL6963555 | 0.99 | EDNRA (0.79) | EDNRAEDNRB | |
| SCHEMBL7503358 | 0.93 | EDNRA (0.69) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29379450 | 0.92 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL1983603 | 0.92 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581324 | 0.92 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974621 | 0.91 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581457 | 0.91 | EDNRA (0.78) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4445 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4616867-A1 | COMBINATION OF ENDOTHELIN RECEPTOR ANTAGONIST AND GLUCOCORTICOID FOR TREATING IGA NEPHROPATHY | Sanreno Therapeutics (Shanghai) Limited (CN) | 2025-09-17 | — | — | EP | claimed |
| EP-4608396-A1 | TREATMENT OF IGA NEPHROPATHY USING AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN APRIL BINDING ANTIBODY | Chinook Therapeutics, Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-06-24 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-120051303-A | Combination of endothelin receptor antagonists and glucocorticoids for the treatment of IgA nephropathy | 信瑞诺医药（上海）有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025103453-A1 | SIRNA FOR INHIBITING ANGIOTENSINOGEN EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | claimed |
| US-20250144095-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CONNECTIVE TISSUE DISORDERS | UNIV JOHNS HOPKINS (US) | 2025-05-08 | — | — | US | claimed |
| US-20250082773-A1 | COMBINATION THERAPY USING EXOSOME SECRETION INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | Research & Business Foundation Sungkyunkwan University (KR) | 2025-03-13 | — | — | US | claimed |
| US-20240392294-A1 | IRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT) | BANK OF AMERICA, N.A. | 2024-11-28 | — | — | US | claimed |
| CN-118853660-A | SiRNA for inhibiting expression of angiotensinogen and application thereof | 纳肽得(青岛)生物医药有限公司 | 2024-10-29 | — | — | CN | claimed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020183347-A1 | Pharmaceutical compositions based on anticholinergics and endothelin antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | US | claimed |
| WO-2002074034-A2 | NOVEL MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGIC AGENTS AND ENDOTHELIN ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-26 | — | — | WO | claimed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | claimed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| US-6316453-B1 | Aqueous pharmaceutical composition | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-11-13 | — | — | US | claimed |
| EP-1060749-A1 | Aqueous pharmaceutical composition comprising Tezosentan | Actelion Pharmaceuticals Ltd. (CH) | 2000-12-20 | — | — | EP | claimed |
| US-6004965-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-12-21 | — | — | US | claimed |
| EP-0799209-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019459-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | claimed |